Molnupiravir

全球50余款新冠药物获批,国产口服特效药进入上市冲刺阶段1、全球新冠药物研发进展迅速，已有50余款药物（含疫苗）获批新冠适应症，国产口服特效药也进入上市冲刺阶段。全球新冠药物研发概况整体研发规模：截至五月初，全球在研新冠药物达1200余...全球50余款新冠药物获批,国产口服特效药进入上市冲刺阶段 1、全球新冠药物研发进展迅速，已有50余款药物（含疫苗）获批新冠适应症，国产口服特效药也进入上市冲刺阶段。全球新冠药物研发概况 整体研发规模：截至五月初，全球在研新冠药物达1200余个，IND及以上阶段占比近50%，提交上市申请15个，涉及企业超1000家。 2、新冠药物之王：截至目前，国外已有两款新冠口服药物获批上市，但国内尚未有新冠治疗药物正式上市。我国国产小分子新冠口服药已有10余款在紧急研发中，多款已进入三期临床试验。其中，真实生物的阿兹夫定和开拓药业的普克鲁胺已完成临床三期试验，处于上市前的最后冲刺阶段。 3、CL蛋白酶抑制剂路线：代表药物是辉瑞的Paxlovid，目前全球基于3CL蛋白酶开发的新冠肺炎药物有40余款，已获批上市的有辉瑞的Paxlovid和仅在日本上市的盐野义Xocova。 4、莫那比拉韦：全球首款抗新冠口服药，由美国默克公司和里奇巴克生物医药公司联合研发，2021年11月在英国获得上市批准。据数据显示，该药可将未接种疫苗的高风险人群住院或死亡风险降低约30%。但科学家担心它可能对人体的DNA或RNA产生影响，具有潜在的致癌突变风险。 5、我国已经上市的新冠药物，包括：新冠病毒中和抗体联合治疗药物安巴韦单抗注射液及罗米司韦单抗注射液（2021年12月获批上市），口服药物阿兹夫定片（2022年7月25日获批上市）。 都五月了,离澳洲对中国学生解封的日子还远吗? 目前无法确定澳洲对中国学生“解封”的具体日期，但已有相关积极信号和初步规划。具体如下：疫情控制情况：澳洲政府抗疫成效显著，新增确诊从3月28日峰值回落，截至当时累计确诊6896例，死亡95例，死亡率4%，累计确诊进入稳定期，疫情得到控制。 英国和澳大利亚计划逐步解禁，并恢复往返中国的国际航班，这对中国留学生而言是重大利好消息，可能使高校正常开学成为可能。 澳洲计划7月重新开放，国际留学生或可在7月返澳并赶上开学季，同时各州公布开学时间，部分大学降低录取要求，政府也在考虑对留学生提供豁免政策。澳洲解封与留学生返澳计划 5月8日，澳洲总理莫里森宣布了「放宽限制的三步走计划」，旨在分阶段恢复企业经营，推动经济复苏，预计7月重新开放澳洲。 中国疾控中心五月疾病提醒 中国疾控中心五月疾病提醒需重点关注新冠肺炎、诺如病毒肠炎、食物中毒、蜱传播疾病和动物源性传染病的预防，具体预防措施如下：新冠肺炎预防 疫苗接种：符合条件而未接种新冠疫苗者（尤其是老年人）尽快接种疫苗，未全程接种者尽快完成全程接种，完成基础免疫接种超过6个月者尽快接种加强针。 容城县疾控中心紧急提醒近期，北京接连出现由社会面散发病例引起的市场、公司、快递物流等重点人群的聚集性疫情，特别是韵达快递长阳分部。5月16日，北京市新增16例韵达快递长阳分中心病例，现已累计确诊45例。 关于2023五一高速免费情况：根据《重大节假日免收小型客车通行费实施方案》，今年五一5天假期，全国收费公路将继续免收小型客车通行费。免费时间从5月1日零时起，至5月5日24时结束。 中国网5月21日讯 “为爱点亮烛光”——2017国际艾滋病烛光纪念日活动今日在中国人民对外友好协会举办。 五月全球疫情依然潜在着极大风险 五月全球疫情确实仍潜在极大风险，可能出现比四月更严峻的形势，具体分析如下：亚非拉地区疫情爆发风险 人口大国持续爆发：俄罗斯、巴西人口过亿，疫情可能持续爆发一段时间。南亚的印度、孟加拉，中东的沙特、阿联酋，拉美的墨西哥、厄瓜多尔、秘鲁、智利等国，都可能在五月中下旬出现爆发高峰。 五月可能是全球疫情最严重的时刻，二季度全球经济衰退已成必然，三四季度经济恢复存在极大不确定性。五月或为全球疫情最严重时刻：亚非拉地区疫情大规模爆发：根据疫情传播规律，五月疫情将在亚非拉更大范围内爆发。目前，欧洲一些小国、亚洲部分国家以及沙特、厄瓜多尔等高温国家疫情数据已破万。 美洲确诊超欧洲：美洲区域累计确诊超196万例，成为全球疫情最严重地区。美国：确诊病例达1482916例，死亡89318例，占全球确诊病例约1/3。巴西：未提供具体数据，但结合其他信息推测为美洲第二大疫情国。秘鲁：确诊92273例，委内瑞拉504例。欧洲：部分国家疫情趋缓，但聚集性传播仍存风险。

CEO Brett Giroir, M.D., said Altesa BioSciences \"will benefit greatly from the participation of Sanofi.\"\n Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm.Altesa BioSciences unveiled back in 2022 with $4 million in seed funding and a mission to build upon the work of the Emory University scientists behind Merck & Co.’s COVID-19 antiviral molnupiravir and a billion-dollar HIV treatment.At the time, CEO Brett Giroir, M.D., a former FDA acting commissioner and admiral, told Fierce that the aim was to be “small, nimble, sort of a special operations-like that we can take molecules, get them into the best indication and prove them or make them fail early so that we can get them to patients.”French Big Pharma Sanofi has since been convinced, hopping on board for today\'s oversubscribed $75 million series B round that was led by Forbion and saw previous investors like Medicxi, Pitango and Atlantic Partners return.“We are honored to have Forbion as our lead investor, a global leader with an unmatched track record for developing companies and products across multiple therapeutic areas,” Giroir said in a Feb. 19 release. “In addition, Altesa will benefit greatly from the participation of Sanofi, given its ongoing expertise in COPD therapeutics.” “By focusing on the true medical need—patients most at risk for hospitalization, death, and long-term decline—we hope to radically improve outcomes and reduce overall healthcare burden,” the CEO added.  Top of the list of priorities for the cash will be a phase 2b study of vapendavir, a once-failed Aviragen drug for the common cold. Altesa in-licensed the broad-spectrum antiviral, which missed the primary endpoint in a phase 2b trial in asthmatic patients with rhinovirus in 2017, to develop it in chronic obstructive pulmonary disease (COPD).Altesa’s plan for the phase 2b study is to enroll 900 COPD patients in the U.S. and U.K., who will then be randomized when they experience rhinovirus infection. Rhinovirus is the most common cause of respiratory exacerbations in patients with COPD and other chronic lung diseases.The trial, which is expected to kick off in the second quarter, will be overseen by Altesa Chief Medical Officer Katharine Knobil, M.D., who joined the company in May 2025 and whose previous roles include holding the position at GSK. The latest study will build on a trial last year of 40 patients with COPD where Altesa was able to point to improved upper and lower airway symptoms as well as reduced illness durations and inflammatory markers. At that point, Altesa was touting vapendavir, which is taken orally as a pill, as the only direct-acting antiviral medicine targeting rhinovirus currently in human clinical trials. “Our trial’s objective is to demonstrate that treatment of rhinovirus respiratory infections can improve symptoms, hasten resolution of illness, and maintain quality of life, while potentially avoiding advanced medical interventions,” Knobil said in this morning\'s release. “For many COPD patients, even a simple cold can lead to an exacerbation, hospitalization, and worsening quality of life—vapendavir has the potential to change that trajectory,” Knobil added.Beyond COPD, Altesa hopes to apply vapendavir to other high-risk respiratory populations, such as patients with asthma.